Legend Biotech (LEGN) Equity Average (2021 - 2025)

Legend Biotech has reported Equity Average for 5 years, with the latest figure at $1.0 billion in Q4 2025.

• For the quarter ending Q4 2025, Equity Average fell 6.65% year-over-year to $1.0 billion; the trailing twelve-month figure through Dec 2025 stood at $1.0 billion (down 6.65% YoY), and the FY2025 full-year result was $1.0 billion, down 10.88% from the prior year.
• Equity Average for Q4 2025 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• The five-year high for Equity Average was $1.4 billion in Q3 2023, with the low at $170.1 million in Q2 2021.
• Historically, Equity Average has averaged $886.5 million across 5 years, with a median of $1.0 billion in 2025.
• Annual changes were most pronounced in 2022 — Equity Average surged 152.03% — and 2024, when it decreased 17.17%.
• Legend Biotech's Equity Average stood at $495.9 million in 2021, then surged by 51.95% to $753.6 million in 2022, then surged by 71.92% to $1.3 billion in 2023, then fell by 16.76% to $1.1 billion in 2024, then decreased by 6.65% to $1.0 billion in 2025.
• The last three Equity Average figures came in at $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025), per Business Quant data.